Peptide Stack
Wolverine Stack (BPC-157 + TB-500)
The most popular healing peptide combination: BPC-157 and TB-500 in a single vial, marketed for injury recovery and gut health. Zero published human trials of the combination.
Summary What is the Wolverine Stack, and does it actually help healing? Show / hide ↓
The Wolverine Stack combines two experimental peptides, BPC-157 and TB-500, usually in a 1:1 mix such as 5 mg of each. BPC-157 is linked to angiogenesis, meaning the growth of new blood vessels, while TB-500 is linked to cell movement and less scar tissue. There are zero published human trials testing the combination, and a 2025 review found no human safety data for either peptide alone or together. The TB-500 sold in these products is not the full-length thymosin beta-4 tested in human trials, which failed to meet its main goal in late-stage studies. Product quality is a major concern: independent testing found about 8% of commercial peptide products contaminated, and both substances are banned in competitive sport.
What this means for you: This combination has only weak, mostly theoretical support and no human trials. It is not enough evidence to buy it, especially given the contamination and safety concerns.
weak evidenceThe Wolverine Stack combines BPC-157 (a 15-amino-acid gastric juice derivative) with TB-500 (a 7-residue fragment of thymosin beta-4) in a single lyophilized vial, typically at a 1:1 mass ratio (5+5 mg or 10+10 mg). It is the single most commercially successful peptide combination in the gray-market peptide space, priced around $74-130 per bundle.
The two peptides have genuinely non-overlapping proposed mechanisms. BPC-157 is associated with local angiogenesis and growth-factor signaling. TB-500 is associated with actin-mediated cell migration and reduced fibrosis. This mechanistic complementarity is the basis for the stack's marketing.
However, zero published human trials have tested the combination. A 2025 systematic review by Vasireddi et al. found no human safety data for either peptide individually or in combination. The TB-500 fragment sold in these stacks is not the molecule tested in human trials: those used full-length recombinant Tbeta4, which missed its primary endpoint in every late-stage program.
Both peptides came off FDA Category 2 in April 2026 and received positive PCAC recommendations in July 2026, meaning legal compounded access may open. However, regulatory reclassification is a procedural step, not an endorsement of efficacy or safety.
Both are WADA-prohibited (TB-500 under S2/S0), so competitive athletes risk sanctions. Neither is approved for human use in any jurisdiction. Product purity is the practical risk: independent testing of commercial peptide products has found roughly 8% contaminated, some with bacterial endotoxins capable of sepsis-like reactions.
Fixed-ratio blends remove the ability to titrate either component independently. If an adverse reaction occurs, there is no way to determine which peptide caused it.
- Peptides
- BPC-157, TB-500 (thymosin beta-4 fragment)
- Typical format
- Pre-blended single vial, 1:1 ratio (10+10 mg or 5+5 mg). Around $74-130 per bundle.
- Marketed for
- Tendon, ligament and muscle injury recovery; gut healing; general 'accelerated healing'
What works
- Two most-researched repair peptides with non-overlapping proposed mechanisms
- Both came off FDA Category 2 in April 2026 with positive PCAC recommendations
- Convenience of a single reconstitution and injection
What to watch for
- Zero published human trials of the combination
- TB-500 fragment is not the molecule tested in human trials (full-length Tbeta4 missed every late-stage endpoint)
- Fixed-ratio blends prevent independent dose titration
- Both WADA-prohibited, unapproved in any jurisdiction
Theoretical angiogenesis-related concern with occult tumors. Product contamination rate approximately 8% in independent testing. Neither peptide is FDA-approved for human use. WADA-prohibited (S2/S0).
Further reading
Curated external sources for a deeper dive. External links open in a new tab.